Published in Nephron Physiol on January 01, 2003
Hospital treatment for fluid overload in the Medicare hemodialysis population. Clin J Am Soc Nephrol (2010) 1.04
Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment. Cardiorenal Med (2015) 0.87
Bioimpedance and echocardiography used interchangeably in volume comparison of dialysis patients. Hippokratia (2012) 0.83
The controversies of diagnosing and treating hypertension among hemodialysis patients. Semin Dial (2012) 0.81
Disordered aldosterone-volume relationship in end-stage kidney disease. J Renin Angiotensin Aldosterone Syst (2009) 0.78
Comprehensive and personalized care of the hemodialysis patient in tassin, france: a model for the patient-centered medical home for subspecialty patients. ISRN Nephrol (2012) 0.78
Assessment of oral health in peritoneal dialysis patients with and without diabetes mellitus. Perit Dial Int (2011) 0.76
Fluid volume expansion and depletion in hemodialysis patients lack association with clinical parameters. Can J Kidney Health Dis (2015) 0.75
[Management strategy for hypertension in chronic hemodialysis: a model applied to patient education (FTE)]. Pan Afr Med J (2014) 0.75
High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant (2009) 3.08
Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant (2010) 2.70
Intensive hemodialysis associates with improved survival compared with conventional hemodialysis. J Am Soc Nephrol (2012) 2.15
Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant (2008) 1.59
Biological impact of targeted dialysate calcium changes in haemodialysis patients: the key role of parathyroid hormone. Nephrol Dial Transplant (2012) 1.52
Assessment of quality guidelines implementation using a continuous quality improvement programme. Blood Purif (2007) 1.46
Plasma BNP, a useful marker of fluid overload in hospitalized hemodialysis patients. Hemodial Int (2012) 1.43
Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat Rev Nephrol (2011) 1.42
Hyperphosphataemia and related mortality. Nephrol Dial Transplant (2005) 1.39
Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant (2008) 1.34
Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int (2009) 1.16
Significance of interdialytic weight gain versus chronic volume overload: consensus opinion. Am J Nephrol (2013) 1.14
Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant (2009) 1.14
Optimal composition of the dialysate, with emphasis on its influence on blood pressure. Nephrol Dial Transplant (2004) 1.05
Vitamin D deficiency and associated factors in hemodialysis patients. J Ren Nutr (2008) 1.04
Long 3 x 8 hr dialysis: a three-decade summary. J Nephrol (2004) 0.95
An epidemiological study of hemodialysis patients based on the European Fresenius Medical Care hemodialysis network: results of the ARO study. Nephron Clin Pract (2010) 0.89
[Calciphylaxis in dialysis patients: To recognize and treat it as soon as possible]. Nephrol Ther (2010) 0.85
Increased levels of serum parathyroid hormone and fibroblast growth factor-23 are the main factors associated with the progression of vascular calcification in long-hour hemodialysis patients. Nephron Clin Pract (2012) 0.84
Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant (2004) 0.83
Sclerostin in CKD-MBD: one more paradoxical bone protein? Nephrol Dial Transplant (2013) 0.80
[Clinical and biological forms of secondary hyperparathyroidism in dialysis patients]. Nephrol Ther (2011) 0.79
High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients. Nephron (2016) 0.78
Intensive dialysis and blood pressure control: a review. Hemodial Int (2004) 0.78
The neglect of sodium restriction in dialysis patients: a short review. Hemodial Int (2003) 0.78
Total and bone-specific alkaline phosphatases in haemodialysis patients with chronic liver disease. Clin Biochem (2012) 0.78
[Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy]. Nephrol Ther (2010) 0.77
[How to deal with those low parathyroid hormone values in dialysis patients?]. Nephrol Ther (2012) 0.76
Vascular Calcification Progression Is an Independent Predictor of Mortality in Patients on Haemodialysis. Nephron (2015) 0.76
[Bone biomarkers in haemodialysis patients: bone alkaline phosphatase or ß-Crosslaps?]. Nephrol Ther (2013) 0.76
Reverse epidemiology and hemodialysis blood pressure. Kidney Int (2003) 0.76
Treating mineral metabolism disorders in patients undergoing long hemodialysis: a search for an optimal strategy. Hemodial Int (2009) 0.76
Dialysis: prognostic value of blood pressure in patients on hemodialysis. Nat Rev Nephrol (2010) 0.75
The debate regarding the reliability of international comparisons of survival on dialysis continues. Hemodial Int (2003) 0.75
Non-infected central venous catheters in hemodialysis patients are not associated with inflammation. Kidney Int (2010) 0.75
[Questions about the ADVANCE study]. Nephrol Ther (2011) 0.75
Urea kinetics on 8-hour hemodialysis: the third slope meaning. Nephron (2002) 0.75
Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism. Nephrol Dial Transplant (2007) 0.75
[How valid are food surveys run by dieticians?]. Nephrol Ther (2009) 0.75
[An efficient strategy to decrease the central venous catheter-related adverse events rate in haemodialysis patients]. Nephrol Ther (2009) 0.75
Individualizing the dialysate calcium concentration. Curr Opin Nephrol Hypertens (2015) 0.75